US Archives - Page 178 of 215 - European Medical Journal

Deep Learning Tool Predicts Immunotherapy Efficacy in Lung Cancer

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

What Do Migraine And Gastrointestinal Disorders Have In Common?

A study has uncovered significant genetic overlap between migraine and several gastrointestinal (GI) disorders, suggesting shared underlying neurologic mechanisms despite diverse etiologies.

Ultrasound Technique Offers Hope for Preventing Epilepsy: AES 2024

Low-intensity focused ultrasound (LOFU) shows promise as a non-invasive treatment for temporal lobe epilepsy (TLE).

COMET Trial Explores DCIS Treatment Dilemma: SABCS 2024

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Data, Risks, and Mortality Rates Of Fungal Infections After HSCT

A recent multicenter study in China provides critical insights into the persistent threat of invasive fungal disease (IFD) among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

RBC Transfusions: New Guidelines for ICU Care

New evidence-based guidelines for red blood cell (RBC) transfusions in critically ill patients have been released, offering critical care practitioners a roadmap to optimize patient outcomes.

Knowledge Gaps Found in Antiseizure Medications and Birth Control: AES 2024

The study surveyed 107 people, aged 18 to 49, who were taking ASMs, asking about their medication use, pregnancy plans, and contraceptive methods…

Risk-Reducing Surgery for BRCA Carriers: SABCS 2024

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.